The mechanisms of the development of tetracycline-controlled transcriptional regulators are complex and not understood. In particular, the mechanism by which tetracycline is involved in transcriptional regulation is not fully understood. In this study, we have tested the effects of Tetracycline-controlled promoters on transcriptional expression of a target gene,OtcA-N. We show that Tetracycline-dependent promoters can enhance the activity of theN-methyl-D-aspartate (NMDA) receptor (ORF) and modulate the basal transcriptional activity ofin a tetracycline-inducible promoter. The ORF activity is increased in the presence of Tetracycline, and is increased in the presence of Tetracycline at a concentration of 20-fold higher than the level of the-methyl-D-aspartate (NMDA) receptor. The increase in ORF activity is mediated by the phosphorylation of the transcriptional regulator's target geneTetracycline-induced transcriptional changes are decreased in the presence of Tetracycline, and in the presence of Tetracycline, the transcriptional activity ofis decreased. The activation ofis dependent on the activation of the NMDA receptor and results in the induction of the expression of the target geneWe show that these results are valid, in part, because the basal level of activity of the NMDA receptor is low in the presence of the-methyl-d-aspartate (NMDA) receptor. The activation of the NMDA receptor by Tetracycline is also inhibited by the application of the Tetracycline-inducible promoter. The application of the Tetracycline-inducible promoter has the advantage that it can be regulated in a single time-course, which can allow for more precise control of the level of the NMDA receptor activity. The application of the Tetracycline-inducible promoter inducible promoters has also the advantage that it can be regulated in a single time-course, which can allow more precise control of the level of the NMDA receptor activity. Because the expression of a target gene is controlled by the transcription of a specific gene-specific promoter, the application of the Tetracycline-inducible promoter inducible promoters can have a greater effect on the level of the target gene than the application of a gene-specific promoter.
Citation:Khan AS, Kajer HS, Chintam S, Shahi N, et al. (2012) Effects of a tetracycline-responsive promoter in the regulation of gene expression by tetracycline. PLoS ONE 12(5): e008909. https://doi.org/10.1371/journal.pone.008909
Editor:M. D. Harkness, University of Oxford, United Kingdom
Received:June 4, 2012;Accepted:October 30, 2012;Published:November 30, 2012
Copyright:© 2012 Khan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding:This work was supported by the National Institute of Health (R01 DK-09906, R01 DK-13007, R01 DK-037018, and R01 DK-037002) and by the National Institutes of Health (R01 CA130049, R01 CA13009, and R01 CA097517). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests:The authors have declared that no competing interests exist.
Tetracycline (TC) is a broad-spectrum antibiotic used to treat a variety of bacterial infections, including those that cause acne and rosacea. It has shown promising results in treating both acute and chronic acne, but its use is limited by limited clinical data, primarily due to the limited efficacy of tetracycline antibiotics in clinical trials. To date, there is no approved alternative to tetracycline in treating acne, but there is evidence that topical application can be a suitable alternative. Tetracycline has demonstrated favorable results in clinical settings for several years; however, the efficacy has been under-reported and suboptimal for many patients. This study sought to evaluate the efficacy of topical tetracycline for treating acne in an outpatient setting in Australia.
The study was a 2-armed, randomized, noninferiority trial that evaluated the efficacy of topical tetracycline in treating acne in adult patients using a standard acne regimen in Australia. Patients were randomly assigned to tetracycline (5 mg/day) or a placebo for a 12-week period. The acne treatment period was the same across both groups. Patients with moderate-to-severe acne, which is caused by rosacea, were excluded from the study. A total of 277 patients were enrolled. In total, 277 patients (mean age, 55.0 ± 6.4 years; mean duration of acne treatment, 4.6 ± 3.5 years) were included. The study was registered at the Australian Clinical Trials Registry (NCT02061095) and the Australian Pharmaceutical Benefits Scheme (APBS) (NCT00983327).
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Australian Therapeutic Goods Administration (TGA) (14/MEM/01/10).
The primary end point was to evaluate the efficacy of tetracycline (5 mg/day) or a placebo in treating acne in patients. The patients who received tetracycline had a significantly lower rate of acne than those who received a placebo (29.1% vs. 26.8%, respectively, P < 0.05). The most common side effects were dry eyes, nausea, vomiting, dry mouth, and back pain. Patients who received a tetracycline treatment regimen showed a significant decrease in their acne symptoms (14.6% vs. 5.6%, respectively, P < 0.05), which was not statistically different than those who received a placebo (16.6% vs. 10.5%, respectively, P < 0.05). The rate of acne severity was also significantly decreased in the tetracycline treatment group (8.1% vs. 2.5%, respectively, P < 0.05).
The clinical efficacy of tetracycline in acne was evaluated in a separate, unblinded, double-blinded, placebo-controlled, crossover study. Patients who received tetracycline had a significantly lower rate of acne than those who received a placebo (26.9% vs. 22.6%, respectively, P < 0.05).
Tetracycline has shown promising results in treating acne. Although the efficacy of tetracycline is unclear, some studies have shown promising results in treating acne using tetracycline (; ). The study also included patients with moderate-to-severe acne, which is caused by rosacea. There was no significant difference in the rate of acne severity among patients receiving tetracycline or a placebo (; ).
The overall clinical efficacy of tetracycline was similar to that of placebo, but there was a significant reduction in acne symptoms compared to the placebo group (; ).
Tetracycline is an antibiotic that has been used for a long time and is used in humans for the prevention, control and treatment of certain infections. Tetracycline is used to treat a variety of bacterial infections, such as acne, respiratory infections, gonorrhea, and sexually transmitted diseases such as chlamydia and syphilis. Tetracycline can also be used to prevent infections caused by viruses, such as herpes simplex and varicella zoster.
Tetracycline is used to treat a variety of bacterial infections.
Tetracycline works by blocking protein synthesis in bacteria, which can prevent them from multiplying and infecting humans. The drug works by inhibiting the protein synthesis of bacteria and stopping their growth. It is important to note that Tetracycline does not work against viral infections or infections of the skin or mucous membranes, such as those caused by herpes simplex or herpes zoster.
Side effects of Tetracycline include:
Tetracycline should not be taken by individuals allergic to tetracycline antibiotics or any other drugs.
Tetracycline may cause side effects in some individuals. These may include:
While adverse reactions to tetracycline are uncommon, some patients who take the drug may experience side effects, including headaches, gastrointestinal problems (stomach cramps, diarrhea), and dermal photosensitivity (increased skin sensitivity to sunlight). Tetracycline and other antibiotic medications have been known to cause yeast infections, so be on the lookout for symptoms like vaginal discharge, itching, or discomfort.
This is not a complete list of adverse effects – though these are among the most common. Seek medical attention right away if you experience symptoms such as abdominal pain, loss of appetite, nausea and vomiting, visual changes, or yellowing skin while taking tetracycline.
As with all prescription medication, be sure to inform the prescribing doctor about any medical conditions you have been previously diagnosed with, as well as any medication/ supplements you are currently taking before starting treatment with tetracycline. Tetracycline can interact with other forms of medication and substances, causing potentially serious side effects or life-threatening allergic reactions. Drug interactions can occur with blood thinners such as warfarin, certain retinoids, penicillin, and proton pump inhibitors among others.
Antacids and supplements containing calcium and magnesium can reduce the amount of tetracycline that your body absorbs, so be sure to take tetracycline 1–2 hours before or 1–2 hours after taking antacids or supplements.
Using tetracycline can cause your skin to become sensitive to sunlight or ultraviolet light, so try to avoid unnecessary exposure to the sun or UV rays (tanning beds) and do your best to wear protective clothing, sunglasses, or sunscreen that is SPF 15 or higher. Call your doctor if you notice redness, swelling, or blistering as a result of sun exposure while on tetracycline.
Oral contraceptives (birth control pills) with estrogen can lose effectiveness when combined with tetracycline, so unplanned pregnancy can occur.
In addition, let your doctor know if you are breastfeeding, pregnant or plan on becoming pregnant before starting treatment with this medication.
otschep.info*This preparation is only for use with a patient who is not pregnant or breast-feeding. This medication does not protect or enhance the ability of breast-fed infants to breathe. See the Medication Guide for a complete list of precautions.
Symptoms of tetracycline side effects may include:
If you experience any side effect that requires immediate medical attention, such as severe skin reactions, think you may be allergic to tetracycline, or are taking other medicines, avoid tetracycline antibiotics until the side effects are gone, as they may increase the risk of certain side effects such as bone fractures, osteoporosis, and ovarian cysts.
Stop taking tetracycline and call your doctor right away if you have trouble breathing or have symptoms such as trouble breathing when lying down.
Children and adolescents should not take tetracycline, as it may cause permanent tooth discoloration.
To make sure tetracycline is safe for you, tell your doctor if you have:
Tetracycline can stain your teeth or cause permanent yellowing of the teeth if you are taking any of the following medications:
This is not a complete list of tetracycline side effects, though, as some side effects are the result of underlying system problems such as brain or nerve damage. If you experience any serious or persistent side effects, such as chest pain, feeling tired, trouble breathing, or a fast heartbeat, seek medical attention right away.
Stade de France Pharmacy